Development and Testing of Complex Molecular Genetic Diagnosis of Genitourinary System Neoplasms
DOI:
https://doi.org/10.15407/scine11.02.035Keywords:
cxcr4 genes, diagnosis, erg, gstp1, malignant neoplasms of genitourinary system, psa, pсa3, tmprss2Abstract
A system for comprehensive non-invasive diagnostic of urogenital system neoplasms has been designed and tested on the basis of molecular genetic parameters (the tmprss2/erg rearrangement using reverse transcriptase polymerase chain reaction (PCR), the level of psa3/psa and cxcr4 gene expression using quantitative PCR, and the gstp1 gene promoter methylation status using methyl-specific PCR.
References
Polyschuk L.A., Stakhovskyj A.E., Teleheev H.D., Stakhovskyj E.A. Sovremennye molekuliarno-henetycheskye podkhody k dyahnostyke onko-zabolevanyj mochepolovoj systemy. Urolohiia, 2010, 14, N 3, pp. 68—76 [in Russian].
Polyschuk L.A., Teleheeva P.H., Stakhovskyj A.E. y dr. Novye spetsyfychnye molekuliarnye dyahnostycheskye markery pry onkourolohycheskykh zabolevanyiakh. Laboratornaia dyahnostyka, 2010, N 4(54), pp. 46—51 [in Russian].
Dubrovska A., Telegeev G. et al. CXCR4 Expression in Prostate Cancer Progenitor Cells. Plos One, 2012, 7(2), e 31226 [in English].
Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinum thiocyanate-phenol-chloroform extraction. Analyt. Biochem, 1987, 162, pp. 156—159 [in English].
https://doi.org/10.1016/0003-2697(87)90021-2
Hessels D., Smit F.P., Verhaegh G.W. et al. Detection of TM PRSS2-ERGFusion transcripts and prostate cancer antigen3 in urinary sediments may improve diagnosis of prostate cancer. Clin. Cancer Res, 2007, 13, pp. 17 [in English].
https://doi.org/10.1158/1078-0432.CCR-07-0700
Cojoc M., Peitzsch C., Trautmann F. et al. Emerging targets in cancer management: role of the CXCL12/CXCR4 axis. Onco Targets and Therapy, 2013, N 6, pp. 1347—1361 [in English].
Bussemakers M.J., van Bokhoven A., Verhaegh G.W. et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res, 1999, Dec 1, 59 (23), pp. 5975—79 [in English].
Kok J.B.,de, Verhaegh G.W., Roelofs R.W. et al. DD3 (PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res, 2002, 62, pp. 2695—98 [in English].
Hessels D., Gunnewiek J.M., van Oort I. et al. DD3 (PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur. Urol., 2003, 44(1), pp. 8—15, discussion 15—6 [in English].
https://doi.org/10.1016/S0302-2838(03)00201-X
Ploussard G.I., Haese A., van Poppel H. et al. The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies? BJU Int., 2010 Oct, 106(8): 1143-7 [in English].
https://doi.org/10.1111/j.1464-410X.2010.09286.x
Day J.R., Jost M., Reynolds M.A. et al. PCA3: from basic molecular science to the clinical lab. Cancer Lett., 2011 Feb 1, 301(1): 1—6 [in English].
https://doi.org/10.1016/j.canlet.2010.10.019
Clarke R.A., Zhao Z., Guo A.Y. et al. New genomic structure for prostate cancer specific gene PCA3 within BMCC1: implications for prostate cancer detection and progression. PLoS One, 2009, 4(3), e4995. doi: 10.1371/journal.pone.0004995, Epub 2009 Mar 25 [in English].
https://doi.org/10.1371/journal.pone.0004995
Auprich M.I., Bjartell A., Chun F.K. et al. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. Eur. Urol., 2011, 60(5), pp. 1045—54 [in English].
https://doi.org/10.1016/j.eururo.2011.08.003
Gyoyao Wu. Glutathione metabolism and its implication for health. J. of Nutrition, 2004, 134(3), pp. 489—492 [in English].
Cao D.L, Yao X.D. Advances in biomarkers for early diagnosis of prostate cancer. Chin. J. Cancer, 2010, 29(2), pp. 220—233 [in English].
https://doi.org/10.5732/cjc.009.10274
Eaton D.L. Concise review of the glutathione S-transferases and their significance to toxicology. Toxicological sciences, 2007, 49, pp. 156—164 [in English].
https://doi.org/10.1093/toxsci/49.2.156
Solonchak A.M., Obolens’ka M.Yu. Struktura i funktsii hlutation-S-transferazy R1. Ukr. bioloh. Zhurnal., 2009, N 1, pp. 5—17 [in Ukrainian].
Bernardini S. et al. Hypermethylation of the CpG in the promotor region of the GSTP gene in prostata cancer: a useful diagnostic and prognostic marker. Clin. Chim. Acta., 2004, 350, pp. 1—2 [in English].
https://doi.org/10.1016/j.cccn.2004.07.022
Bastian P.J., Ellinger G., Schmidt D. et al. GSTP1 hypermethylation as a molecular marker in the diagnosis of prostate cancer: is there correlation with clinical stage. Eur. J. Med. Res., 2004, N 9(11), pp. 523—527 [in English].
Dulaimi E. et al. Promoter Hypermethylation Profile of Kidney Cancer. Clin. Cancer Res., 2004, N 10, pp. 3972—3979 [in English].
https://doi.org/10.1158/1078-0432.CCR-04-0175
Battagli C., Uzzo R.G., Dulaimi E. Promoter hyper methylation of tumor suppressor genes in urine from kidney cancer patients. Cancer Res., 2003, 63, pp. 8695—8699 [in English].
Clark S. et. al. DNA methylation: Bisulphite modification and analysis. Nature Protocols, 2006, N 1, pp. 2353—2364 [in English].
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Copyright Notice Authors published in the journal “Science and Innovation” agree to the following conditions: Authors retain copyright and grant the journal the right of first publication. Authors may enter into separate, additional contractual agreements for non-exclusive distribution of the version of their work (article) published in the journal “Science and Innovation” (for example, place it in an institutional repository or publish in their book), while confirming its initial publication in the journal “Science and innovation.” Authors are allowed to place their work on the Internet (for example, in institutional repositories or on their website).
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
